+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Rare Endocrine Disease Treatment - Global Strategic Business Report

  • PDF Icon

    Report

  • 194 Pages
  • March 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5309819

Global Rare Endocrine Disease Treatment Market to Reach $12.9 Billion by 2030

The global market for Rare Endocrine Disease Treatment estimated at US$9.8 Billion in the year 2022, is projected to reach a revised size of US$12.9 Billion by 2030, growing at a CAGR of 3.5% over the analysis period 2022-2030. Acromegaly, one of the segments analyzed in the report, is projected to record 4.1% CAGR and reach US$5.2 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Central Diabetes Insipidus segment is readjusted to a revised 3.6% CAGR for the next 8-year period.

The U.S. Market is Estimated at $2.9 Billion, While China is Forecast to Grow at 3.2% CAGR

The Rare Endocrine Disease Treatment market in the U.S. is estimated at US$2.9 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$2.3 Billion by the year 2030 trailing a CAGR of 3.2% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.4% and 2.8% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3.5% CAGR.

Select Competitors (Total 41 Featured) -

  • Amgen, Inc.
  • Corcept Therapeutics, Inc.
  • Eli Lilly and Company
  • EMD Serono, Inc.
  • Ipsen Group
  • Novartis AG
  • Novelion Therapeutics, Inc.
  • Novo Nordisk A/S
  • Pfizer, Inc.
  • Shire PLC
  • Teva Pharmaceutical Industries Ltd.

What's New?

  • Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
  • Global competitiveness and key competitor percentage market shares
  • Market presence across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to digital archives and Research Platform
  • Complimentary updates for one year

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Rare Endocrine Disease Treatment - Global Key Competitors Percentage Market Share in 2022 (E)
  • Impact of Covid-19 and a Looming Global Recession
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for Rare Endocrine Disease Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 2: World Historic Review for Rare Endocrine Disease Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 3: World 16-Year Perspective for Rare Endocrine Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
  • Table 4: World Recent Past, Current & Future Analysis for Acromegaly by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 5: World Historic Review for Acromegaly by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 6: World 16-Year Perspective for Acromegaly by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 7: World Recent Past, Current & Future Analysis for Central Diabetes Insipidus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 8: World Historic Review for Central Diabetes Insipidus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 9: World 16-Year Perspective for Central Diabetes Insipidus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 10: World Recent Past, Current & Future Analysis for Ahumada-Del Castillo Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 11: World Historic Review for Ahumada-Del Castillo Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 12: World 16-Year Perspective for Ahumada-Del Castillo Syndrome by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 13: World Recent Past, Current & Future Analysis for Hypoparathyroidism by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 14: World Historic Review for Hypoparathyroidism by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 15: World 16-Year Perspective for Hypoparathyroidism by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 16: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 17: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 18: World 16-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 19: World Rare Endocrine Disease Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • Table 20: World Recent Past, Current & Future Analysis for Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 21: World Historic Review for Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 22: World 16-Year Perspective for Injectables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 23: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 24: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 25: World 16-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 26: World Recent Past, Current & Future Analysis for Other Modes of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 27: World Historic Review for Other Modes of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 28: World 16-Year Perspective for Other Modes of Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
III. MARKET ANALYSIS
  • UNITED STATES
  • Rare Endocrine Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
  • Table 29: USA Recent Past, Current & Future Analysis for Rare Endocrine Disease Treatment by Indication - Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 30: USA Historic Review for Rare Endocrine Disease Treatment by Indication - Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 31: USA 16-Year Perspective for Rare Endocrine Disease Treatment by Indication - Percentage Breakdown of Value Sales for Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications for the Years 2014, 2023 & 2030
  • Table 32: USA Recent Past, Current & Future Analysis for Rare Endocrine Disease Treatment by Mode of Administration - Injectables, Oral and Other Modes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 33: USA Historic Review for Rare Endocrine Disease Treatment by Mode of Administration - Injectables, Oral and Other Modes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 34: USA 16-Year Perspective for Rare Endocrine Disease Treatment by Mode of Administration - Percentage Breakdown of Value Sales for Injectables, Oral and Other Modes of Administration for the Years 2014, 2023 & 2030
  • CANADA
  • Table 35: Canada Recent Past, Current & Future Analysis for Rare Endocrine Disease Treatment by Indication - Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 36: Canada Historic Review for Rare Endocrine Disease Treatment by Indication - Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 37: Canada 16-Year Perspective for Rare Endocrine Disease Treatment by Indication - Percentage Breakdown of Value Sales for Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications for the Years 2014, 2023 & 2030
  • Table 38: Canada Recent Past, Current & Future Analysis for Rare Endocrine Disease Treatment by Mode of Administration - Injectables, Oral and Other Modes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 39: Canada Historic Review for Rare Endocrine Disease Treatment by Mode of Administration - Injectables, Oral and Other Modes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 40: Canada 16-Year Perspective for Rare Endocrine Disease Treatment by Mode of Administration - Percentage Breakdown of Value Sales for Injectables, Oral and Other Modes of Administration for the Years 2014, 2023 & 2030
  • JAPAN
  • Rare Endocrine Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
  • Table 41: Japan Recent Past, Current & Future Analysis for Rare Endocrine Disease Treatment by Indication - Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 42: Japan Historic Review for Rare Endocrine Disease Treatment by Indication - Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 43: Japan 16-Year Perspective for Rare Endocrine Disease Treatment by Indication - Percentage Breakdown of Value Sales for Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications for the Years 2014, 2023 & 2030
  • Table 44: Japan Recent Past, Current & Future Analysis for Rare Endocrine Disease Treatment by Mode of Administration - Injectables, Oral and Other Modes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 45: Japan Historic Review for Rare Endocrine Disease Treatment by Mode of Administration - Injectables, Oral and Other Modes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 46: Japan 16-Year Perspective for Rare Endocrine Disease Treatment by Mode of Administration - Percentage Breakdown of Value Sales for Injectables, Oral and Other Modes of Administration for the Years 2014, 2023 & 2030
  • CHINA
  • Rare Endocrine Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
  • Table 47: China Recent Past, Current & Future Analysis for Rare Endocrine Disease Treatment by Indication - Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 48: China Historic Review for Rare Endocrine Disease Treatment by Indication - Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 49: China 16-Year Perspective for Rare Endocrine Disease Treatment by Indication - Percentage Breakdown of Value Sales for Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications for the Years 2014, 2023 & 2030
  • Table 50: China Recent Past, Current & Future Analysis for Rare Endocrine Disease Treatment by Mode of Administration - Injectables, Oral and Other Modes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 51: China Historic Review for Rare Endocrine Disease Treatment by Mode of Administration - Injectables, Oral and Other Modes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 52: China 16-Year Perspective for Rare Endocrine Disease Treatment by Mode of Administration - Percentage Breakdown of Value Sales for Injectables, Oral and Other Modes of Administration for the Years 2014, 2023 & 2030
  • EUROPE
  • Rare Endocrine Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
  • Table 53: Europe Recent Past, Current & Future Analysis for Rare Endocrine Disease Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 54: Europe Historic Review for Rare Endocrine Disease Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 55: Europe 16-Year Perspective for Rare Endocrine Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
  • Table 56: Europe Recent Past, Current & Future Analysis for Rare Endocrine Disease Treatment by Indication - Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 57: Europe Historic Review for Rare Endocrine Disease Treatment by Indication - Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 58: Europe 16-Year Perspective for Rare Endocrine Disease Treatment by Indication - Percentage Breakdown of Value Sales for Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications for the Years 2014, 2023 & 2030
  • Table 59: Europe Recent Past, Current & Future Analysis for Rare Endocrine Disease Treatment by Mode of Administration - Injectables, Oral and Other Modes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 60: Europe Historic Review for Rare Endocrine Disease Treatment by Mode of Administration - Injectables, Oral and Other Modes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 61: Europe 16-Year Perspective for Rare Endocrine Disease Treatment by Mode of Administration - Percentage Breakdown of Value Sales for Injectables, Oral and Other Modes of Administration for the Years 2014, 2023 & 2030
  • FRANCE
  • Rare Endocrine Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
  • Table 62: France Recent Past, Current & Future Analysis for Rare Endocrine Disease Treatment by Indication - Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 63: France Historic Review for Rare Endocrine Disease Treatment by Indication - Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 64: France 16-Year Perspective for Rare Endocrine Disease Treatment by Indication - Percentage Breakdown of Value Sales for Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications for the Years 2014, 2023 & 2030
  • Table 65: France Recent Past, Current & Future Analysis for Rare Endocrine Disease Treatment by Mode of Administration - Injectables, Oral and Other Modes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 66: France Historic Review for Rare Endocrine Disease Treatment by Mode of Administration - Injectables, Oral and Other Modes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 67: France 16-Year Perspective for Rare Endocrine Disease Treatment by Mode of Administration - Percentage Breakdown of Value Sales for Injectables, Oral and Other Modes of Administration for the Years 2014, 2023 & 2030
  • GERMANY
  • Rare Endocrine Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
  • Table 68: Germany Recent Past, Current & Future Analysis for Rare Endocrine Disease Treatment by Indication - Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 69: Germany Historic Review for Rare Endocrine Disease Treatment by Indication - Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 70: Germany 16-Year Perspective for Rare Endocrine Disease Treatment by Indication - Percentage Breakdown of Value Sales for Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications for the Years 2014, 2023 & 2030
  • Table 71: Germany Recent Past, Current & Future Analysis for Rare Endocrine Disease Treatment by Mode of Administration - Injectables, Oral and Other Modes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 72: Germany Historic Review for Rare Endocrine Disease Treatment by Mode of Administration - Injectables, Oral and Other Modes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 73: Germany 16-Year Perspective for Rare Endocrine Disease Treatment by Mode of Administration - Percentage Breakdown of Value Sales for Injectables, Oral and Other Modes of Administration for the Years 2014, 2023 & 2030
  • ITALY
  • Table 74: Italy Recent Past, Current & Future Analysis for Rare Endocrine Disease Treatment by Indication - Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 75: Italy Historic Review for Rare Endocrine Disease Treatment by Indication - Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 76: Italy 16-Year Perspective for Rare Endocrine Disease Treatment by Indication - Percentage Breakdown of Value Sales for Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications for the Years 2014, 2023 & 2030
  • Table 77: Italy Recent Past, Current & Future Analysis for Rare Endocrine Disease Treatment by Mode of Administration - Injectables, Oral and Other Modes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 78: Italy Historic Review for Rare Endocrine Disease Treatment by Mode of Administration - Injectables, Oral and Other Modes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 79: Italy 16-Year Perspective for Rare Endocrine Disease Treatment by Mode of Administration - Percentage Breakdown of Value Sales for Injectables, Oral and Other Modes of Administration for the Years 2014, 2023 & 2030
  • UNITED KINGDOM
  • Rare Endocrine Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
  • Table 80: UK Recent Past, Current & Future Analysis for Rare Endocrine Disease Treatment by Indication - Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 81: UK Historic Review for Rare Endocrine Disease Treatment by Indication - Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 82: UK 16-Year Perspective for Rare Endocrine Disease Treatment by Indication - Percentage Breakdown of Value Sales for Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications for the Years 2014, 2023 & 2030
  • Table 83: UK Recent Past, Current & Future Analysis for Rare Endocrine Disease Treatment by Mode of Administration - Injectables, Oral and Other Modes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 84: UK Historic Review for Rare Endocrine Disease Treatment by Mode of Administration - Injectables, Oral and Other Modes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 85: UK 16-Year Perspective for Rare Endocrine Disease Treatment by Mode of Administration - Percentage Breakdown of Value Sales for Injectables, Oral and Other Modes of Administration for the Years 2014, 2023 & 2030
  • REST OF EUROPE
  • Table 86: Rest of Europe Recent Past, Current & Future Analysis for Rare Endocrine Disease Treatment by Indication - Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 87: Rest of Europe Historic Review for Rare Endocrine Disease Treatment by Indication - Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 88: Rest of Europe 16-Year Perspective for Rare Endocrine Disease Treatment by Indication - Percentage Breakdown of Value Sales for Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications for the Years 2014, 2023 & 2030
  • Table 89: Rest of Europe Recent Past, Current & Future Analysis for Rare Endocrine Disease Treatment by Mode of Administration - Injectables, Oral and Other Modes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 90: Rest of Europe Historic Review for Rare Endocrine Disease Treatment by Mode of Administration - Injectables, Oral and Other Modes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 91: Rest of Europe 16-Year Perspective for Rare Endocrine Disease Treatment by Mode of Administration - Percentage Breakdown of Value Sales for Injectables, Oral and Other Modes of Administration for the Years 2014, 2023 & 2030
  • ASIA-PACIFIC
  • Rare Endocrine Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
  • Table 92: Asia-Pacific Recent Past, Current & Future Analysis for Rare Endocrine Disease Treatment by Indication - Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 93: Asia-Pacific Historic Review for Rare Endocrine Disease Treatment by Indication - Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 94: Asia-Pacific 16-Year Perspective for Rare Endocrine Disease Treatment by Indication - Percentage Breakdown of Value Sales for Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications for the Years 2014, 2023 & 2030
  • Table 95: Asia-Pacific Recent Past, Current & Future Analysis for Rare Endocrine Disease Treatment by Mode of Administration - Injectables, Oral and Other Modes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 96: Asia-Pacific Historic Review for Rare Endocrine Disease Treatment by Mode of Administration - Injectables, Oral and Other Modes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 97: Asia-Pacific 16-Year Perspective for Rare Endocrine Disease Treatment by Mode of Administration - Percentage Breakdown of Value Sales for Injectables, Oral and Other Modes of Administration for the Years 2014, 2023 & 2030
  • REST OF WORLD
  • Table 98: Rest of World Recent Past, Current & Future Analysis for Rare Endocrine Disease Treatment by Indication - Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 99: Rest of World Historic Review for Rare Endocrine Disease Treatment by Indication - Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 100: Rest of World 16-Year Perspective for Rare Endocrine Disease Treatment by Indication - Percentage Breakdown of Value Sales for Acromegaly, Central Diabetes Insipidus, Ahumada-Del Castillo Syndrome, Hypoparathyroidism and Other Indications for the Years 2014, 2023 & 2030
  • Table 101: Rest of World Recent Past, Current & Future Analysis for Rare Endocrine Disease Treatment by Mode of Administration - Injectables, Oral and Other Modes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 102: Rest of World Historic Review for Rare Endocrine Disease Treatment by Mode of Administration - Injectables, Oral and Other Modes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 103: Rest of World 16-Year Perspective for Rare Endocrine Disease Treatment by Mode of Administration - Percentage Breakdown of Value Sales for Injectables, Oral and Other Modes of Administration for the Years 2014, 2023 & 2030
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Amgen, Inc.
  • Corcept Therapeutics, Inc.
  • Eli Lilly and Company
  • EMD Serono, Inc.
  • Ipsen Group
  • Novartis AG
  • Novelion Therapeutics, Inc.
  • Novo Nordisk A/S
  • Pfizer, Inc.
  • Shire PLC
  • Teva Pharmaceutical Industries Ltd.

Table Information